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Abstract
Plasminogen activator inhibitor type-I (PAI-I ) is a serpin superfamily member protein that acts as the major
inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). At
physiological levels, PAI-I plays an active role in regulating fibrinolysis, the process of normal blood clot
degradation. Pathological levels of PAI-I have been linked to multiple health ailments: fibrosis, heart disease,
cancer, and obesity. In recent years, PAI-1 has been the subject of targeted drug design. In this study, we
identified a class of polyphenol compounds as the most capable of maintaining its inhibitory efficiency against
vitronectin bound PAI-I in buffer and plasma. Additionally, a previously reported class of biphenyl amide PAI-
I inhibitors was structurally probed to determine the pharmacophore. We provide evidence supporting the
anti-PAI-I pharmacophore as the carboxylic acid moiety, observing modifications to this group significantly
reduces potency. Furthermore, to assess if the in vivo metabolites of the biphenyl amides were active against
PAl-1, structurally inspired metabolites were tested and found to yield no activity.
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Abstract 
Plasminogen activator inhibitor type-I (PAI-I )  is a serpin superfamily member protein 
that acts as the major inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type 
plasminogen activator (uPA). At physiological levels, PAI-I plays an active role in regulating 
fibrinolysis, the process of normal blood clot degradation. Pathological levels of PAI-I have 
been linked to multiple health ailments: fibrosis, heart disease, cancer, and obesity. In recent 
years, PAI-1 has been the subject of targeted drug design. In this study, we identified a class of 
polyphenol compounds as the most capable of maintaining its inhibitory efficiency against 
vitronectin bound PAI-I in buffer and plasma. Additionally, a previously reported class of 
biphenyl amide PAI-I inhibitors was structurally probed to determine the pharmacophore. We 
provide evidence supporting the anti-PAI-I pharmacophore as the carboxylic acid moiety, 
observing modifications to this group significantly reduces potency. Furthermore, to assess if the 
in vivo metabolites of the biphenyl amides were active against PAl-1, structurally inspired 
metabolites were tested and found to yield no activity. 
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Introduction 
Plasminogen activator inhibitor type-I (PAI-I) is a serine protease inhibitor (serpin) 
superfamily member that targets tissue type plasminogen activator and urokinase type 
plasminogen activator (tPA and uPA, respectively). 1 The 379-amino acid length structure of 
PAI-I is comprised of 9 a-helices, 3 P-sheets and a 20- amino acid length reactive center loop 
(RCL). i,2 PAI-I is essential, at normal levels, for the regulation of many biological processes 
like fibrinoiysis and wound healing due to its influence on blood clot degradation. 3 Active tPA 
and uP A trigger a cascade of events that initiates the breakdown of fibrin, a mesh-like protein 
that is the major component of blood clots (Figure I ). Thus, PAI-1 's ability to inhibit 
plasminogen activator(PA) results in the persistence of blood clots. Pathological levels of PAI - I  
have been linked to  a myriad of medical ailments including fibrosis, cancer, strokes, heart 
disease, diabetes, and obesity. 4• s, 6• 7• 8 PA I-I has been identified as a potential target for drug 
design in hopes of producing a therapy for said ailments. To date, there are no clinically 
approved drugs that are known to act through the inhibition of PAl-1. 
Plasmlnogen 
Activator 
amount a/ PA I.,_ __ 
Decreased 1 
remain active 
[ -·-l Decreased 
proteolytic 
cltovoge 
Pathaloglcal 
PAl-1 
Decreased 
Plasmln 
Reduced 
Blood Cot 
Degradation 
Figure 1. The effects of pathological PAI- I  on fibrinolysis. 
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The mechanism by which PAI-I acts on PAs is referred to as kinetic trapping. 9 This 
mechanism, displayed by the serpin superfamily, observes PA seeking out a sequence in the PAI­
I RCL, binding it, and attempting to proteolytically cleave it. During this interaction, the RCL 
inserts into one of the protein's P-sheets. If the PA finishes its catalytic cycle before the RCL 
insertion is completed, it will be released in its active fonn and PAI-I will be left in its inactive 
cleaved state. 2 If the PA is unable to finish its catalytic cycle, it will remain bound to the PAI-I 
RCL as it is inserted into the P-sheet. At this point, the PA is incapable cleaving the RCL, 
remaining bound to PAI-I, and is inactivated. The PAI-I bound to inactive PA structure is 
referred to as a Michaelis-Menten type complex. 10 
The insertion of the RCL into the P-sheet during kinetic trapping is thermodynamically 
favorable. 11 In fact, PAI-I will undergo this conformational change in the absence of PA. This 
sees PAI-I go from its less stable, active conformation to its more stable, latent conformation. 4 
Upon converting to the latent conformation, PAI-I no longer yields the ability to inhibit PA, 
much like the cleaved conformation. 
The lack of clinically approved PAI-I inhibitors is indicative of the many challenges 
facing the design of a small-molecule inhibitor of PAI-I that functions in vitro and in vivo. This 
includes yielding no clear active site to target, possessing a flexible reactive center loop, and 
adopting various conformations: active, latent and cleaved (Figure 2). 2 Despite these obstacles, 
many PAI-I inhibitors have been reported and one, tiplaxtinin, entered phase one clinical trials 
with no further progression. 12 It has been observed that many PAI-I inhibitors do not maintain 
their efficiency as they are tested in progressively more complex biological media (bovine serum 
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albumin, human plasma and animals). As there are many factors to consider with regards to the 
loss of activity, the interaction of PAI-I with the cofactor vitronectin has been suggested to be a 
significant agent in the loss of efficiency of certain PAI-I inhibitors. 13 
Active Latent Cleaved 
Figure 2. PAl-1 confonnations. 
Vitronectin is a plasma glycoprotein that is known to bind to, and stabilize, active PAI-I 
in vilro and in vivo. The conformational change to the latent conformation is halted by 
vitronectin as it blocks the spreading of the strands within the beta-sheet, preventing the insertion 
of the RCL that is required for the conversion to the latent confonnation. This action by 
vitronectin significantly increases the half-life of active PAI-I (~90 min) by 2-4 fold. 14 PAI-I is 
frequently found to be bound to vitronectin whenever it is present. 15•16 Thus, any confonnational 
changes or sites of interaction that might be blocked by vitronectin can result in significant 
changes to the activity of PAI-I inhibitors. 
To develop an optimal PAI-I inhibitor, capable of progressing past phase one clinical 
trials, that is more selective, potent, and safe, it is essential to understand how interactions with 
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vitronectin affect PAI-I inhibition. In this study, we assessed the effect of vitronectin on the 
potency of known small-molecule inhibitors of PAI-I. This was completed by evaluating the 
anti-PAI-I activity in various vitronectin-containing media such as human plasma, BSA and 
buffer with added vitronectin. Optimally a class of inhibitor that maintains, or elevates, its anti­
PAl-1 potency in the presence of vitronectin will be identified. For this study, we tested a wide 
array of previously reported PAI-I inhibitors including: arylsulfonamides, 17 a biphenyl amide, 18 
tannic acid, 13 a thiazole, 19 polyphenols, 13, 20 and tiplaxtinin. 12 
In addition to identifying an inhibitor that is selective of vitronectin bound PAI-I, we 
aimed to assess a new class of PAI-I inhibitors that have been reported in literature (Figure 3). 18 
Our initial analysis of this molecule observed that the compound's efficiency is elevated upon 
moving from a buffer media ([Cso= 44 µM) to plasma (ICso= 19 µM). This encouraged further 
investigation of this structure as an explanation for why this class of inhibitor is far more 
efficient in plasma has not been reported. 
Cl 
H 
N 
Figure 3. Biphenyl amide reported by Miyata 
Moving from buffer to plasma places the compound in an environment with enzymes that 
may have the propensity to metabolize and modify the compound. The formation of metabolites 
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in vivo has been observed to enhance the therapeutic effects of many drugs, this is referred to as 
pharmacological activation. 21 Furthermore, the identification of the active metabolite can 
provide insight that produces a more efficacious drug. 22 We propose that such structural 
modifications could explain the elevation of efficiency in vivo. Identifying the active metabolite 
may yield a more efficacious PAI-I inhibitor. In this study, we predicted potential metabolic 
products based on the molecular structure and evaluated them against PAI-I in buffer. 
To further probe this structure, we aimed to identify the pharmacophore of the inhibitor. 
This will provide a site to target for modifications that might lead to a superior inhibitor. A series 
of compounds with modifications throughout the structure were produced and the structure 
activity relationship of the compound was assessed. Primarily, we wished to identify which 
structural feature(s) of the inhibitor is essential to its activity. Through this series of experiments, 
we hope to shed light on the complex nature of P Al-I and identify new scaffolds for the 
synthesis of new, novel classes of PAI-I inhibitors. 
Materials & Methods 
Preparation of buffer solutions for vitronectin study: 
To assess the inhibitors in buffer, buffer containing vitronectin, and human plasma the 
following buffer solution was employed (40mM HEPES, pH 7.4, 100 mM NaCl, 0.005% (VN) 
Tween 20, and 5% (VN) DMSO). To assess the inhibitors in a BSA-containing media the 
following buffer solution was employed ( 40mM HEP ES, pH 7.4, 1 00mM NaCl, 0.005% (V N) 
Tween 20, 5% (V N) DMSO, and 1.5% (W N) BSA) was used. 10. 13 9 
Preparation of human PAI-1 (hPAl-1) solutions for vitronectin study: 
To analyze the inhibitors in the buffer and BSA-containing media, human PAl-1 (hPAI-
1) was incubated in its respective buffer. To analyze the inhibitors in human plasma, hPAI-1 was 
incubated in hPAl-1 depleted plasma containing IO µg/ml aprotinin. To analyze the activity of 
the inhibitors in the presence ofbuffer containing vitronectin media, hPA-1 is incubated in buffer 
containing 7.5 �Lg/ml human vitronectin and stirred for 5 minutes prior to being added to the 
assay system. 13 
Synthesis of PAI-1 inhibitors: 
The synthesis of the compounds in this study are described in the Supplemental 
Information. 
PAI-1 activity assay: 
The preparation and running of the PAl-1 activity assay was carried out at 25 °C. In a 96-
well micro test hPAl-1 is incubated in increasing concentrations of the inhibitor (appropriate 
concentration ranges were determined for each compound to identify their respective anti-PAI-I 
ICso) in the respective buffer, yielding I nM hPAl-1 , and is stirred for 1 5  minutes. uPA yielding 
1 .25 nM is added to the solution and is stirred for 30 minutes. N-Carbobenzyloxy-Gly-Gly-Arg-
7-amido-4-methylcoumarin (AMC-GGR) is added to the solution, yielding a 50 �LM, and 
fluorescence spectroscopy is conducted promptly after addition. AMC-GGR is a substrate that is 
recognized and cleaved by uPA, releasing free AMC that is excited at 370 nm and emits at 440 
nm. Control solutions lacking PAI-I and solutions lacking the inhibitor are produced and read 
simultaneously. The solution is excited at 370 nm, and the fluorescent signal is measured at 440 
10 
nm. The derivative of each solution is read over 10  minutes, yielding 28 measurements. The 
increase in fluorescent signal in inversely proportional to PAI-I activity. 
The lCso values were calculated by measuring the activity differences between each 
solution sample and its respective control containing no PAI-1 . A scatter plot of these values was 
produced in GraphPad Prism, comparing the concentration of inhibitor vs percent PAI-I activity. 
The data were fit with a sigmoid function to identify the ICso for each inhibitor. Additionally, if 
the solutions containing no inhibitor produce lower than normal PAI-I activity, the experiment 
was reassessed for potential errors. 
1H and 13C NMR spectra were obtained with the JEOL ECX-400 spectrometer, 
employing 400 MHz and 1 00 MHz respectively. Deuterated solvents were used in these studies 
and yielded the following reference signals at the following chemical shifts for I H NMR and Be 
NMR, respectively: chloroform (1 H: 6 7.26; 13C: 77. 1 6), acetone (1H NMR: o 2.05; 13C: 29.84 
and 206.26), dimethyl sulfoxide (1 H: o 2.50; 1 3C: 39.52). NMR spectra were processed using 
MestReNova analysis software. Direct analysis in real time mass spectrometry (DART-MS) 
were carried out using a JEOL AccuTOFDART system by Dr. Ruth Ann Armitage. 
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Hypothesis of Vitronectin Study 
The identification of a class of inhibitors that acts against PAI-I bound to vitronectin will 
translate into efficiency that is maintained in vivo. 
Results/ Discussion of Vitronectin Study 
A loss of activity was observed across all the assessed inhibitors in the BSA-containing 
media compared to those using the minimal buffer system (Table I). This suggests that BSA 
yields an elevated propensity for interfering with the activity ofa broad structural class of PAI-I 
inhibitors. The arylsulfonamide (I), bis-arylsulfonamide (2), and tiplaxtinin (3) showed 
significant loss of activity in plasma and buffer+ vitronectin compared to their profiles in buffer. 
One possible explanation for this observation is the presence of vitronectin interfering with the 
compounds ability to effectively interact with PAI-I. 
When compared to their activity in buffer, the biphenyl amide (4) and oxindole (5) both 
lost activity in the buffer+ vitronectin media. The activity of the oxindole in plasma was reduced 
compared to its performance in buffer. The biphenyl amide, however, gained activity in plasma 
when compared to buffer. This suggests that a factor is present in plasma that is not present in 
buffer to elevate the biphenyl amide's efficiency enough to negate any loss due to vitronectin. 
The polyphenol (7) showed a significant loss of activity in plasma but only a moderate 
reduction, by a factor of 4, in the buffer+ vitronectin media. This suggests that the performance 
in plasma might be due to other factors in addition to vitronectin. Tannie acid (6) performed 
similarly to the tripolyphenol (7), however, in plasma the compound showed excessive 
12 
variability across multiple runs and the ICso could not be determined. Tannie acid's efficacy in 
the buffer+ vitronectin media decreased by a factor of I 0. The dipolyphenol (8) maintained its 
efficiency in plasma and was the only compound that increased its activity in buffer+ 
vitronectin, a 21-fold improvement. This provides evidence that the polyphenol compounds, 
particularly the dipolyphenol, are worth pursuing further due to their apparent ability to interact 
with vitronectin bound PAI-I . 
Table I. Inhibitor action against PAI-I in various media. 
Entry 
2 
3 
(Tiplaxtinin) 
4 
s 
6 
(Tnnnic Acid) 
7 
8 
Structure 
:o''\, 
»'\o: 
,/J.-0 
QE�Pu 
:°'rw 
:ck .JS-
53'-ftO..·. .. .. l Kr 
D 0 :xr·x�= 
""ql•-r�= NO "' D 
°"' o..l.to 
6-... 
IC50 (pM) 
Buffer BSA Plasma Buffer+ 
Vitronectin 
16.7 >300 >300 >300 
0.663 >3 >3 >3 
28.3 >1000 >1000 >tooo• 
46 >3000 29 629 
7.15 >300 18.9 54.1 
0.00928 >300 ND 0.0013 
0.166 >10 :>lO 0.668 
3.TI >10 3.236 0.175 
* Somatomedin B (SSB) employed in place of vitronectin, derived proteo/ytical/y from the N-terminus of 
vitronectin. IJ. 23 
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Compared to their activity in buffer, the biphenyl amide (4) and mdndole (5) both lost 
activity in the buffer + vitronectin media. The activity of the oxindole in plasma was reduced 
compared to its performance in buffer. The biphenyl amide, however, gained activity in plasma 
when compared to buffer. This suggests that a factor is present in plasma that is not present in 
buffer that elevates the biphenyl amide's efficiency enough to negate any loss due to vitronectin. 
The polyphenol (7) showed a significant loss of activity in plasma but only a moderate 
reduction, by a factor of 4, in the buffer + vitronectin media. This suggests that the performance 
in plasma might be due to other factors in addition to vitronectin. Tannie acid (6) performed 
similarly to the tripolyphenol (7), however, in plasma the compound showed excessive 
variability across multiple runs and the ICso could not be determined. Tannie acid's efficacy in 
the buffer + vitronectin media decreased by a factor of l 0. The dipolyphenol (8) maintained its 
efficiency in plasma and was the only compound that displayed an increase in activity in buffer + 
vitronectin, a 2 I -fold increase. This provides evidence that the polyphenol compounds, 
particularly the dipolyphenol, are worth pursuing further. 
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Hypothesis of Miyata Compound Metabolites Study 
We hypothesize that phannacological activation is responsible for the elevation anti-PAI­
i activity in vivo. Based on the structure we proposed that the cleavage of the amide bond 
produces an active metabolite that inhibits PAI-I. 
Results/ Discussion of Pharmacophore Study 
Based on the chemical structure of the parent compound, we predicted the cleavage of the 
amide bond is likely to occur in vivo. This could be completed through hydrolysis or protease 
activity. Thus, we tested the respective aniline and carboxylic acid that would be generated upon 
the hydrolysis of the parent structure. We proposed the 2-amino-5-chlorobenzoic acid, produced 
from hydrolysis, can undergo additional metabolic modification. Thus, we suggested the 
oxidative conversion of the amino group to yield a nitro group (Figure 4). 
► 
H
O
X
0
_NH2 
Clu 
H
O 
Figure 4. Proposed metabolites of Miyata compound 
These proposed metabolites were available for purchase and were not synthesized in the Emal 
lab. 
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Based on our analysis, we found that none of our proposed metabolites were active 
against PAI-I (Table 2). More advanced methods can be employed (radiotracing, incubation 
assays, as well as LC-MS, NMR, and mass spectrometry metabolomics) 24• 25,26 to produce more 
likely metabolites of this class of compounds in vivo. The identification of an active metabolite 
of this compound will provide an opportunity to design a better PAI-1 inhibitor that yields 
elevated potency in vivo. 
Table 2. Anti-PAI-I activity of proposed Miyata metabolites 
�NH, HO �N02 
Cl Cl 
ICso (µM) 
Buffer >100 >100 >100 
1.5% BSA >100 >100 >100 
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Hypothesis of Pharmacophore Study 
The carboxylic acid functional group is an essential pharmacophore of the previously 
reported biphenyl amide PAI-I inhibitors. 
Results/ Discussion of Pharmacophore Study 
The compounds were synthesized from their respective starting biphenyl carboxylic acid. 
Various substituents on the terminal phenyl ring were employed to assess the effect of 
modifications to the biphenyl structure on anti-PAI- I activity. Additionally, this synthesis 
produced a compound with an ester functional group in place of the carboxylic acid found in the 
parent compound. The products of scheme I were assessed to determine if the carboxylic acid is 
a pharmacophore of the inhibitor. Scheme } 
HO + 
0 
Cl�
C
I 
0 
C: DMF 
► 
THF 
25°C 
H 
--:::: N 
00 0 
Cl I ll 0 
Compound 
1 
To assess the effect of the modifications to the biphenyl group, the ester was converted to 
a carboxylic acid as shown in scheme 2. This allowed for the isolated evaluation of the biphenyl 
modifications and the proper determination of this structure as a pharmacophore. 
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Scheme 2 
b 1 N  NaOH H -...::::: N ► Cl I b 0 THF 50°c bH N Cl O 
Com120und 
m-CH3 
H 
o-CF3 
m-F 
To gauge the significance of the carboxylic acid functional group to this structure's anti­
PAI-1 activity, we replaced it with a hydrazide group, which is also polar and capable of 
hydrogen bonding. Additionally, the hydrazide has been observed to be an essential piece of 
efficient inhibitors that have been previously synthesized in the Emal lab. Scheme 3 describes 
the synthesis of the hydrazide analogs. 
Scheme 3 
H 
-...::::: N 
�o o 
CJ I b 0 
H2N
�
HN O
H 
-----►- -...::::: N 
I EtOH 
60°C Cl 
b 0 
Com120und 
10 
11  
Upon their successful synthesis, the target compounds were sent to the lab of Dr. Daniel 
Lawrence at the University of Michigan Medical School. The compounds were evaluated for 
their anti-PAI-I activity as previously described (Table 3). 
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Compounds 1-5 demonstrate that replacing the acid with an ester is detrimental to 
activity in both buffer and BSA. Similarly, replacing the acid with a hydrazide (I 0-1 1 )  yielded a 
similar loss of activity. These observations provided evidence that the presence of the carboxylic 
acid is essential to the structure' s  function. Furthermore, compounds 6-9 showed no significant 
loss of activity despite the various modifications to the terminal phenyl ring. This suggests that 
the terminal phenyl ring is far more tolerable of modification in the derivation of future analogs. 
The evidence supports our hypothesis of the carboxylic acid's role as a pharmacophore in this 
structure. 
Compound 
2· 
3 
4 
5 
6* 
7 
8 
9 
10 
1 1  
Table 3. Miyata analogs anti-PAI-I activity 
bH N Cl O 
y X 
OCH3 H 
OCHa m-CH3 
OCH3 o-CFa 
OCH3 m-F 
OCH3 p-F 
OH m-CH3 
OH H 
OH o-CF3 
OH m-F 
NHNH2 H 
NHNH2 o-CF3 
ICso (1,1M) 
Buffer 1 .5% BSA 
>300 >300 
>100 >100 
>300 >300 
>100 >100 
>100 >100 
>100 20 
44 >1000 
>300 22 
>300 20 
>100 >100 
>100 >100 
*Synthesized by Tommy Lepley. 
nt indicates that the compound was not tested in plasma 
Plasma 
>300 
nt 
nt 
nt 
nt 
nt 
19 
nt 
nt 
nt 
nt 
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Further assessment of this inhibitor class is needed to determine if other structural 
features are significant to its anti-PAI-I activity and assess the tolerability of the carboxylic acid 
with further modifications. We have attempted to synthesize a series of analog compounds that 
replace the carboxylic acid with I 0, 2° and 3° amides. These syntheses were unsuccessful and 
future work will be conducted to probe this structure. 
Conclusion: 
Based on our analysis of PAI-I in the presence of vitronectin, the data support the further 
study and optimization of the polyphenols as they appear to hold an elevated affinity for 
vitronectin bound PAI- I .  Creating new scaffolds that incorporate polyphenolic moieties may 
lead to a far more selective inhibitor of PAI-I in biological environments, where vitronectin is 
present. 
The analysis of the Miyata structure indicated that the acts of cleaving the amide bond 
and oxidizing the resulting aniline did not yield compounds with anti-PAI-I activity. Additional 
metabolic routes must be proposed and tested to verify pharmacological activation as an 
explanation for their enhanced efficiency in plasma. Furthermore, the structural probing of this 
structure determined the carboxylic acid to be a pharmacophore against PAI- I .  Modifying this 
site could lead to the identification of a more potent pharmacophore and thus a more potent PAI­
I inhibitor. Probing the structure to identify additional sites essential to anti-PAI-I activity will 
provide sites for new modifications that lead to the development of novel, small molecule 
inhibitors. 
20 
Supplementary Information 
Reagents were procured from Alfa Aesar, Ark Pharm, Koptec, Matrix Scientific, 
Oakwood Chemicals, Sigma Aldrich, and VWR Analytical. Solvents used for NMR analysis 
were purchased from Cambridge Isotope Laboratories, Inc. 
JXP-1-39 (3): A solution was produced under nitrogen gas by combining 2'-trifluoromethyl­
biphenyl-3-carboxylic acid (0.6113 g, 2.296 mmol) and dry dimethylformamide (catalytic 
amount) in dry tetrahydrofuran ( 1 6.0 mL ). The solution was stirred in an ice bath for IO minutes. 
To the cooled solution oxalyl chloride (0.230 I mL, 2.638 mmol) was added and the solution was 
stirred for 30 minutes. The reaction mixture was concentrated in vacuo to afford a light brown 
oil. The oil was diluted in a solution of methyl-5-chloroanthranilate (0.3511, 1 .892 mmol) in 
tetrahydrofuran (8.0 mL). The reaction mixture was diluted in ethyl acetate (20 mL) and washed 
with brine ( I x), 0.2 N HCI (2x), saturated aqueous NaHCO3 (2x) and brine ( Ix). The organic 
layer was dried over magnesium sulfate and evaporated in vacuo to afford 0.5849 g (78.6% 
yield) of JXP-1-39 as a light brown solid. 
1H NMR (CDCh, 400 mHz) o 3.96 (s, 3H), 7.25-8.05 (m, JOH), 8.92 (d, J=9. I Hz, I H), 1 1.99 (s, 
IH) 
21 
F 
JXP-1-41 (4): A solution was produced under nitrogen gas by combining 3'-tluorobiphenyl-3-
carboxylic acid (0.4933 g, 2.282 mmol) and dry dimethylfonnamide (catalytic amount) in dry 
tetrahydrofuran (1 6.0 mL). The solution was stirred in an ice bath for t 0 minutes. To the cooled 
solution oxalyl chloride (0.230 t mL, 2.638 mmol) was added and the solution was stirred for 30 
minutes. The reaction mixture was concentrated in vacuo to afford a brown oil. The oil was 
diluted in a solution of methyl-5-chloroanthranilate (0.3574, t .926 mmol) in tetrahydrofuran (8.0 
mL). The reaction mixture was diluted in ethyl acetate (20 mL) and washed with brine ( I x), 0.2 
N HCI (2x), saturated aqueous NaHCO3 (2x) and brine ( 1  x). The organic layer was dried over 
magnesium sulfate and evaporated in vacuo to afford 0.2077 g (28.7% crude yield) of JXP-1 -41 
as a light, tan solid. 1H NMR analysis of this solid showed a large amount of impurity, expected 
to be starting aniline. Recrystallization in absolute ethanol yielded 4.5 mg of a light brown solid 
(0.63% yield). 
1H NMR (CDCb, 400 MHz) 5 3.99 (s, 3H), 6.59-8.27 (m, I0H), 8.94 (d, J = 9. 1 Hz, t H), 12.07 
(s, I H) 
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JXP-1-42 (5): A solution was produced under nitrogen gas by combining 3-(4-
fluorophenyl)benzoic acid (0.4998 g, 2.312 mmol) and dry dimethylfonnamide (catalytic 
amount) in dry tetrahydrofuran (16.0 mL). The solution was stirred in an ice bath for 1 0  minutes. 
To the cooled solution oxalyl chloride (0.2301 mL, 2.638 mmol) was added and the solution was 
stirred for 30 minutes. The reaction mixture was concentrated in vacuo to afford a brown oil. The 
oil was diluted in a solution of methyl-5-chloroanthranilate (0.3550, 1 .91 3 mmol) in 
tetrahydrofuran (8.0 mL). The reaction mixture was diluted in ethyl acetate (20 mL) and washed 
with brine ( I x), 0.2 N HCI (2x), saturated aqueous NaHCOJ (2x) and brine ( I x). The organic 
layer was dried over magnesium sulfate and evaporated in vacuo to afford 0.1681 g (22.9% 
yield) of JXP- 1 -42 as an orange solid. 
1H NMR (CDCb, 400 MHz) cS 3.98 (s, 3H), 7. 17-8.23 (m, 1 OH), 8.93 (d, J = 9.1 Hz, l H), 12.04 
(s, I H) 
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JXP-1-82 (1): A solution was produced under nitrogen gas by combining 3-biphenylcarboxylic acid (0.9764 g, 4.93 mmol) and dry dimethylformamide (catalytic amount) in dry tetrahydrofuran (33.0 mL). The solution was stirred in an ice bath for l O minutes. To the cooled solution oxalyl chloride (0.500 mL, 5. 74 mmol) was added and the solution was stirred for 30 minutes. The reaction mixture was concentrated in vacuo to afford a brown oil. The oil was diluted in a solution of methyl 2-amino-5-chlorobenzoate (0. 7622 g, 4. 1 0  mmol) in tetrahydrofuran ( 1 6.0 mL). The solution was stirred for 6 days at room temperature. The reaction mixture contained white solid. The solution was concentrated in vacuo, dissolved in diethyl ether and filtered. The filtrate was washed with saturated aqueous NaHCOJ (2x) and brine (2x). The organic layer was left to dry out on the benchtop overnight and was dried in vacuo to yield 1 .3239 g (88.3% yield) of a coarse white solid. 1H NMR (CDCb, 400 MHz) o 3.97 (s, 3H), 7.39-8.28 (m, 1 I H), 8.94 (d, J ""  9. I Hz, I H), 1 2.02 (s, 1 H) 
24 
JXP-1-8S (10): JXP-1-82 (0.1039 g, 0.2733 mmol) was dissolved in 3 mL absolute ethanol. 
NH2NH2•H2O was added to the stirring solution (0.1 57 mL, 2.70 mmol). The solution was 
stirred at 60 °C for two hours. The heat was removed and the solution continued stirring at room 
temperature for two weeks. The solution was filtered and washed with cold, absolute ethanol. A 
white precipitate was yielded and dried in vacuo to afford 0.0390 g (39.0% yield) of JXP-1-85. 
1H NMR (CDCb with a drop of CO3OO, 400 MHz) cS 4.14 (s, 2 H), 7.34-8.22 (m, I 0H), 8.73 (d, 
J = 9.0 Hz, I H), 8. 78 (s, I H), 1 1 .96 (s, I H) 
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JXP-1-54 (11): JXP-1-39 (0.0707 g, 0.1 789 mmol) was dissolved in 2 mL absolute ethanol. 
NH2NH2•H2O was added to the stirring solution (0. 1 1 0  mL, 1 .  772 mmol). The solution 
continued stirring at 60 °C for 3 hours. As the solution cooled to room temperature, white 
crystals began to form. The solution was placed in the freezer overnight, yielding more white 
crystals. The solution was filtered and washed with cold, absolute ethanol. A white precipitate 
was yielded and dried in vacuo to afford 0.0365 g (47.5% yield) of JXP-1-54. 
1H NMR (CDCb, J = 400 Hz) o 1 .54 (s, 3H), 4.09 (s, 2H), 7.36-8.02 (m, l OH), 8.79 (d, J = 9.0 
Hz, l H), 1 1 .75 (s, I H) 
1 H NMR analysis showed all protons of JXP-1 -54 except the a-proton of the hydrazine. 
However, the presence of the B-protons (-NH2) at 4.09 ppm suggests that the hydrazine was 
successfully bound. We confirmed the structure with mass-spec and 13C NMR. 
13C NMR (CDCh + 1 drop CD3QD, J = 1 00 MHz) o 1 68. 1 7, 1 65.58, 140.58, 140. 1 8  (q, J = 2.0), 
137.93, 1 34.00, 132.75, 132.47, 1 3 1 .97, 1 3 1 .55, 128.30, 1 28.24, 1 28. 10, 1 27.85, 1 27.04, 1 26.29, 
126. 12  (q, J = 5.4 Hz), 123.98 (q, 268 Hz), 1 22.74, 120.46, 77.39. 
HRMS, DART calculated (M+H): 434.08578; found: 434.08830. Calculated (2M+H): 
867 . 1 6229; found: 867. 1 6877 
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JXP-1-72 (8): To a solution of JXP-1-39 (0.1003 g, 0.2312 mmol) in tetrahydrofuran (3 mL) 
stirring at 50 °C, 1 N NaOH ( 1.2 mL) was added. The reaction progress was tracked by thin layer 
chromatography (I :10 MeOH:DCM). After I hour, the ester starting material was consumed. 
The reaction solution was concentrated in vacuo, filtered, and dried in vacuo to afford 88.8 mg 
(91.8%) of an orange solid. 
1 H NMR (DMSO-d6, 400 MHz) o 7.43-8.10 (m, 1 OH), 8.94 ( d, J = 9. 1 Hz, 1 H), 12.3 7 (s, I H) 
F 
JXP-1-74 (9): To a solution of JXP-1-41 (0.1 001 g, 0.2608 mmol) in tetrahydrofuran (3 mL) 
stirring at 50 °C, IN N aO H ( 1 .2 mL) was added. The reaction progress was tracked by thin layer 
chromatography (1  :IO MeOH:DCM). After 1 hour, the ester starting material was consumed. 
The reaction solution was concentrated in vacuo, filtered, and dried in vacuo to afford 80.4 mg 
(80.7%) of a coarse, white solid. 
1H NMR (acetone-d6, 400 MHz) o 7.1-8.28 (m, JOH), 8.96 (d, J = 9.0 Hz, I H), 12.25 (s, l H) 
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JXP-1-90 (7): To a solution of JXP-1-82 (0.9998 g, 2.733 mmol) in tetrahydrofuran (36 mL) 
stirring at 50 °C, IN NaOH (14.5 mL) was added. The reaction progress was tracked by thin 
layer chromatography ( 1 : I O  MeOH:DCM). After I hour, the ester starting material was 
consumed. The reaction solution was concentrated in vacuo, filtered, and dried in vacuo to afford 
0.9441 g (96.0%) of a white solid. 
1H NMR (DMSO-d6, 400 MHz) o 7.36-8.25 (m, 1 1  H), 8.70 (d, J = 8.8 Hz, I H) 
The sample contained a significant amount of water, which could explain why the amide proton 
was not observed at ~ o 12.2 as it has been previously. The structure was confirmed using 13C 
NMR. 
13C NMR (DMSO-d6, 100 MHz) o 1 20.85, 1 25.88, 126.14, 1 26.52, 126.78, 127.36, 128.43, 
129.66, 130.00, 130.47, 130.82, 131.20, 1 36.34, 139.98, 1 40.32, 1 41 .17, 1 64.77, 169.05 
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